We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current NOXOF market cap is 13.15M. The company's latest EPS is AUD -0.0122 and P/E is -8.20.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 8.33M | 5.66M | 5.43M | 6.01M | 2.4M |
| Operating Income | -9.13M | -15.59M | -9.78M | -10.65M | -4.6M |
| Net Income | -272k | -9.35M | -18.67M | -15.06M | -3.58M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 20.07M | 47.85M | 26.59M | 10.13M | 6.78M |
| Total Liabilities | 7.19M | 7.08M | 2.48M | 1.06M | 1.29M |
| Total Equity | 12.87M | 40.78M | 24.12M | 9.07M | 5.5M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -11.14M | -8.85M | -13.73M | -10.95M | -684k |
| Investing | 338k | 225k | N/A | 124k | N/A |
| Financing | 14.99M | 28.33M | 976k | -178k | N/A |
| Market Cap | 13.15M |
| Price to Earnings Ratio | -8.20 |
| Price to Sales Ratio | 12.2 |
| Price to Cash Ratio | 12.66 |
| Price to Book Ratio | 5.32 |
| Dividend Yield | - |
| Shares Outstanding | 292.24M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 50.00% |
| 52 Week High | 0.045 |
| 52 Week Low | 0.03 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Noxopharm Ltd (PK) |
| Address |
level 20 sydney, new south wales 2067 |
| Website | https://www.noxopharm.com |
| Industry | drugs and proprietary-whsl (5122) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
